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Aims Recent studies have demonstrated the importance of chromatin remodelling via histone
acetylation/deacetylation for the control of cardiac gene expression. Speciﬁc histone deacetylases
(HDACs) can, in fact, play a positive or negative role in determining cardiac myocyte (CM) size. Here,
we report on the effect on hypertrophy development of three inhibitors (HDACi) of class I HDACs.
Methods and results The compounds were ﬁrst analysed in vitro by scoring hypertrophy, expression of
foetal genes, and apoptosis of neonatal rat CMs stimulated with phenylephrine, an a1-adrenergic
agonist. This initial screening indicated that a truncated derivative of apicidin with class I HDAC
speciﬁcity, denoted API-D, had the highest efﬁcacy to toxicity ratio, and was thus selected for
further analysis in vivo. Administration of this drug signiﬁcantly decreased myocardial hypertrophy
and foetal gene expression after 1 week of pressure overload induced by thoracic aortic constriction
(TAC) in mice. After 9 weeks of TAC, when manifest heart failure is encountered, mice treated with
API-D presented with signiﬁcantly improved echocardiographic and haemodynamic parameters of
cardiac function when compared with untreated TAC-operated mice.
Conclusion The apicidin derivative, API-D, is capable of reducing hypertrophy and, consequently, the
transition to heart failure in mice subjected to TAC. Treatment with this substance, therefore, holds
promise as an important therapeutic option for heart failure.
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1. Introduction
Histone deacetylases (HDACs) remodel chromatin in a gene-
speciﬁc fashion by changing nucleosomal packaging of
DNA: deacetylation of histones H3 and H4 by HDACs inhibits
transcription, whereas their acetylation by histone acetyl-
transferases (HATs) results in transcriptional activation.1
HDACs, thus, can regulate important cellular functions
through gene expression control. In particular, regulation
of histone acetylation is implicated in proper cell function,
differentiation, and cell growth.2,3 The pharmacological
inhibition of HDACs has, therefore, raised signiﬁcant interest
in the pharmaceutical industry particularly in the search for
new anti-proliferative molecules.
Mammalian HDACs can be divided into four classes based on
their sequence motifs and catalytic mechanisms.4,5 Class I, II,
and IV HDACs are evolutionarily related Znþ-dependent
hydrolases. The members of class I (HDAC1, -2, -3, and -8)
are expressed ubiquitously and consist mainly of a deacety-
lase domain. Class II HDACs (HDAC4, -5, -7, and -9) are
highly expressed in muscle, brain, and T cells. They have an
extended N-terminus, which serves as a target for protein–
protein interactions and for post-translational modiﬁcations,
such as phosphorylation, important for their function and
governing nuclear-cytoplasmic shuttling.6 HDAC11 is con-
sidered to be structurally diverse enough from the other Znþ-
dependent HDACs to be classiﬁed as a separate class (class
IV).7 Class III HDACs are related to the yeast HDAC, silent
information regulator 2, and use nicotinamide adenine
dinucleotide as a co-substrate.8
With regard to myocardial hypertrophy, studies have
demonstrated that HDACs suppress this process.9,10 Moreover,
† These authors contributed equally to the work.
*Corresponding author. Tel: þ1 858 822 5010; fax: þ1 858 822 3027.
E-mail address: gcondorelli@ucsd.edu
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2008.
For permissions please email: journals.permissions@oxfordjournals.org.
Cardiovascular Research (2008) 80, 416–424
doi:10.1093/cvr/cvn215
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/article-abstract/80/3/416/323136 by BIBLIO
TEC
A FAC
O
LTA' M
ED
IC
IN
A VETER
IN
AR
IA user on 22 July 2019
inhibition of general HDAC activity has also been reported to
suppress hypertrophy.11,12 It was suggested that different
classes of HDACs suppress distinct sets of hypertrophic
program-inﬂuencing genes. For example, whereas class II
HDACs suppress pro-hypertrophic genes, class I HDACs might
repress expression of anti-hypertrophic genes. If the anti-
hypertrophic gene products were dominant over the genes
suppressed by class II HDACs, one would expect HDAC
inhibitors to block hypertrophy. Accordingly, inhibition of
class I HDACs would result in a de-repression of such anti-
hypertrophic genes and consequently block hypertrophy.
There is evidence for a potential role of class I HDACs in
cardiac growth, but the mechanism is still undeﬁned and
even less clear than for class II HDACs.13,14
In addition, evidence from rodent models indicates that
cardiac function is preserved when hypertrophy is inhibited
in the face of stress signalling. This points to the potential
importance of therapeutic strategies that modulate the
hypertrophic process.15–22
In the present study, we have deﬁned the binding speci-
ﬁcity of novel HDAC inhibitors (HDACis) and have evaluated
the role of speciﬁc inhibitors of class I HDACs in the preven-
tion of cardiac hypertrophy in vitro and in vivo. Our data
suggest that class I HDAC inhibition has potential use in
heart failure.
2. Methods
2.1 In vitro histone deacetylase inhibition assays
C-terminally ﬂag-tagged HDAC1, -2, -3, -6, -9, and -11 were
expressed in HEK293 cells, afﬁnity puriﬁed using anti-ﬂag antibody
afﬁnity resin, and eluted with a 3X ﬂag peptide. HDAC4, -5, -7,
and -8 were expressed in Escherichia coli. The obtained molecules
were then puriﬁed to apparent homogeneity [Coomassie-stained
sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS–PAGE)] by nickel afﬁnity then anion-exchange (MonoQ) chrom-
atographies, and ﬁnally, by gel ﬁltration. IC50 values of the inhibitor
molecules were then determined using the HDAC Fluorescent
Activity Assay (BioMol Research Laboratories).
2.2 Histone deacetylase inhibitors
Three HDAC inhibitors, MS27-275, PXD-101, and API-D, were chosen
based on suitable pharmacokinetic properties and bioavailability for
in vivo studies. MS27-275 is an aminobenzamide23 with selectivity
for HDAC1, -2, and -3 when assayed on a panel of puriﬁed HDAC sub-
types. PXD-101 belongs to the hydroxamic acid class of inhibitors24
and inhibits both class I and class II enzymes, albeit with different
potencies. The third inhibitor, API-D, is a derivative of the cyclic
peptide, apicidin, a structurally novel HDAC inhibitor;25 it also
shows selectivity for HDAC class I subtypes 1, 2, and 3 (Table 1).
2.3 In vitro experimentation
Cardiomyocytes (CMs) were obtained as previously described from
3-day-old neonatal Wistar rat pups (Charles River Laboratories).26
CMs were seeded on gelatin-coated plates and kept overnight in
medium containing 15% serum to which mitomycin (Sigma) had
been added to inhibit overgrowth of non-cardiomyocytes. Cultures
contained ,95% CMs as assessed by immunoﬂuorescence for
cardiac troponin I (Chemicon). The morning following seeding,
CMs were washed, treated with HDACi and/or phenylephrine (PE),
and assayed as described later.
2.3.1 Treatment with histone deacetylase inhibitors and
induction of hypertrophy
The morning following seeding, CMs were washed in phosphate
buffered saline (PBS) and pre-treated in serum-free medium con-
taining HDACi at the indicated doses. A medium change was done
24 h later, again with serum-free medium containing HDACi. Hyper-
trophy was then induced by the addition of 50 mM PE. CMs were
cultured for a further 48 h before analysis. Vehicle [DMSO (dimethyl
sulphoxide)] was used instead of HDACi in Control samples. Where
speciﬁed, the non-speciﬁc HDACi, trichostatin A (TSA), was used
as a positive control of HDAC inhibition, and the MEK-1/2 inhibitor,
PD 098059 (Calbiochem), was used as a control for the inhibition of
PE-induced hypertrophy.27
2.3.2 Western blotting
Plates were placed on ice and the CMs washed with ice-cold PBS,
scraped and centrifuged. Pelleted CMs were lysed directly in
Laemlli’s sample buffer, boiled for 3 min, centrifuged, and loaded
onto 12% SDS–PAGE. After transfer onto polyvinylidene ﬂuoride,
membranes were blocked with 5% milk tris-buffered saline-tween
20 and incubated with the following primary antibodies: anti-acetyl
histone H3 and anti-histone H4 (Upstate); anti-acetyl tubulin
(Sigma); anti-actin; and anti-GAPDH (glyceraldehyde-3-phosphate
dehydrogenase; Chemicon). Secondary antibodies and enhanced
chemiluminescence were from Amersham. For in vivo experiments,
hearts were snap frozen in liquid N2, pulverized with a pestle and
mortar, and lysed with radio-immunoprecipitation assay buffer.
Sample buffer was then added to the uncleared lysates.
2.3.3 Ribonucleic acid extraction and real-time
polymerase chain reaction
For in vitro experiments, total ribonucleic acid (RNA) was extracted
using the RNeasy mini kit (Qiagen) according to the manufacturer’s
instructions. The reverse transcription (RT) reaction was performed
using Superscript III reverse transcriptase and random primers (Invi-
trogen). Real-time polymerase chain reaction (PCR) was performed
in an ABI PRISM 7000 instrument (Applied Biosystems) using TaqMan
technology for Caspase 3 (Casp3), atrial natriuretic factor (ANF),
and skeletal actin (Sk Act), as recommended by the manufacturer.
For in vivo experiments, total RNA was extracted by TRIZOL
(Invitrogen) according to the manufacturer’s instructions. The RT
reaction was then performed as the in vitro experiments. Real-time
PCR was performed for Casp3, ANF, brain natriuretic peptide (BNP),
Sk Act, and beta-myosin heavy chain (b-MHC).
To detect Casp3, Sk Act, BNP, and b-MHC, TaqMan oligonucleo-
tides (Assay on Demand, Applied Biosystems) were used, whereas
Table 1 IC50 data (nM) of the histone deacetylase (HDAC)
inhibitors for single class I, II, and IV HDACs
Class HDAC MS27–275 PXD-101 API-D
I 1 171 57 13
2 421 88 18
3 337 25 11
8 28 780 56 .1000
II 4 .50 000 4581 .1000
5 .50 000 7018 .1000
6 .50 000 40 680
7 .50 000 2008 .1000
9 n.d. n.d. n.d.
10 n.d. n.d. n.d.
IV 11 .50 000 19 540 n.d.
Values are means of three or more experiments. n.d., not determined.
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for ANF, speciﬁc primers (For: 50-GGA GGA GAA GAT GCC GGT
AGA-30; Rev: 50-GCT TCC TCA GTC TGC TCA CTC A-30) (PRIMM) and
a speciﬁc probe (FAM-TGA GGT CAT GCC CCC GCA GG-TAMRA)
(Applied Biosystems) were designed with the ‘Primer Express’
Program (Applied Biosystems).
The Assays on Demand used are given in the see Supplementary
material online, Materials and Methods. All reactions were per-
formed in duplicate. 22DDCT values were normalized with the
values obtained for ampliﬁcation of GAPDH (Assay on Demand,
Applied Biosystems).
2.3.4 Morphometrical measurements
Before preparing CMs for the analyses mentioned earlier, plates
were photographed under a phase contrast microscope at 200
magniﬁcation. Captured images were then analysed with Scion
Image software (Scion Corp. Inc.) to obtain CM area data expressed
in square pixels.
2.3.5 Immunoﬂuorescence
Fixed CMs were stained with phalloidin-tetramethyl rhodamine
iso-thiocyanate (Sigma) or anti-cardiac troponin (Chemicon) and
counterstained with 40,6-diamino-2-phenylindole (DAPI).
2.3.6 Lactate dehydrogenase release and terminal
deoxynucleotidyl transferase biotin-20-deoxyuridine
50-triphosphate nick end labelling analysis
Culture supernatants were collected after 24 and 72 h of treatment
with HDACi. Lactate dehydrogenase (LDH) released into the super-
natants was quantiﬁed with the CytoTox 96w Assay Kit (Promega),
following the manufacturer’s indications. Supernatant from
vehicle-treated CMs was used for background subtraction. Data
are expressed as arbitrary units.
CMs, seeded in 24-well plates and treated as mentioned earlier,
were ﬁxed in paraformaldehyde and processed with a terminal
deoxynucleotidyl transferase biotin-20-deoxyuridine 50-triphosphate
nick end labelling (TUNEL) kit (Roche), as indicated by the manufac-
turer. DAPI (Sigma) was used to counterstain the nuclei. Images,
captured under a ﬂuorescence microscope, were then analysed to
obtain the number of TUNEL-positive nuclei per ﬁeld. A minimum
of 200 cells per point were counted. Data are expressed as a
percentage of DAPI-stained nuclei.
2.4 In vivo experimentation
This investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996), and Italian minis-
terial authorization (art. 7, DL 116/92) was obtained to carry out
the experimentation.
Nine-week-old female C57BL/6 mice (Charles River Laboratories)
(n ¼ 7 per group) were subjected to transverse aortic constriction
(TAC) surgery with standard procedures and then treated intraperito-
neally (i.p.) with API-D starting from day 1 after TAC. At the indicated
time-points, histological, haematological, echocardiographic, and
invasive haemodynamic analyses were carried out as outlined later.
2.4.1 Transverse aortic constriction
On day 0, mice were anaesthetized with a ketamine (100 mg/
kg)-xylazine (2.5 mg/kg) mixture administered i.p. and then
connected to a rodent ventilator after tracheal intubation.22 The
chest cavity was opened with scissors by a small incision at the
level of the second intercostal space. After isolation of the aortic
arch, a 7–0 silk suture was placed around the aorta and a 27–27,
5G needle. The needle was immediately removed to produce an
aorta with a stenotic lumen. The chest cavity was then closed
with one 6–0 nylon suture and all layers of muscle and skin closed
with 6–0 continuous absorbable and nylon sutures, respectively.
Sham-operated animals, which underwent surgery without the
ﬁnal tightening of the constrictive suture, were used as Controls.22
2.4.2 Administration of histone deacetylase inhibitors
Mice were treated i.p. with 3 mg/kg of API-D per day six times a
week for 2 weeks, starting on day 1. This dose was found to be
well tolerated. Our data also suggested that higher doses of the
compound could be administered safely over prolonged periods
and, as a result, we decided to use a slightly higher dose (5 mg/kg
per day six times a week for 8 weeks, starting on day 1) for the
long-term efﬁcacy studies to increase the likelihood of observing
effects in our functional in vivo readouts.
Prior to these experiments, pharmacokinetic data were generated
in CD-1 mice (n ¼ 3 mice evaluated per time-point). For this, API-D
was solubilized in PEG400:water 1:1 and dosed at 3 mg/kg by i.p.
injection. A time-course for API-D plasma concentration was also
generated.
2.4.3 Echocardiographic assessment of left
ventricular function
Transthoracic echocardiography was performed to evaluate left
ventricular (LV) function non-invasively in isoﬂurane-anaesthetized
closed-chest mice using a SONOS 5500 echocardiograph (Agilent
Technology) ﬁtted with an 8–15 MHz linear array transducer. LV end-
systolic and end-diastolic dimensions, and wall thicknesses were
evaluated by 2D M-mode as previously described.28 Analysis was
performed at the speciﬁed times before and after TAC.
2.4.4 Invasive haemodynamic assessment
of cardiac function
In vivo LV function was assessed by pressure volume catheter.
Mice were anaesthetized with ketamine (100 mg/kg) and xylazine
(2.5 mg/kg) and connected to a rodent ventilator after endotra-
cheal intubation. Then, bilateral vagotomy cardiac catheterization
was performed using a 1.4 French (0.46 mm) conductance catheter
(Scisense Inc., London, Ontario, Canada) inserted retrograde
through the right carotid artery into the LV. Absolute volume was
calibrated, and steady-state pressure and volume measurements
were digitally recorded at 1000 (baseline). Pressure and volume
measurements were also acquired during transient reduction of
venous return. All experiments were carried out blind and data
were analysed as previously described.29
2.4.5 Histology
Hearts (n ¼ 5 per group) at week 4 of experimentation were quickly
removed from anaesthetized mice and processed for histology using
standard methods. Longitudinal sections of whole heart (4 mm
thick) were stained with Masson’s trichrome to evidence ﬁbrosis.
The total area affected by ﬁbrosis in the sections obtained was quan-
tiﬁed with image analysis software (Software NIS Elements-AR, Nikon
Instruments) by two independent pathologists and expressed as mm2.
2.5 Statistical analysis
Data are expressed as mean+ SD. Multigroup comparisons were
performed using one- or two-way analysis of variance (ANOVA)
with post hoc correction for multiple comparisons as appropriate.
For all analyses, P, 0.05 was considered signiﬁcant.
3. Results
To explore the effects of the HDACis selected for this study,
in vitro experiments on neonatal rat CMs were initially per-
formed. As HDAC suppression would be expected to induce
histone hyperacetylation, due to unopposed HAT activity,
we examined the acetylation status of two known HDAC
targets, nuclear histone H3 and cytosolic a-tubulin, with
western blotting of total cellular extracts (Figure 1A).
HDACi was added to cultured CMs at various concentrations
for 2 h and acetylation then assessed. As expected, all the
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HDACis used were capable of inducing a signiﬁcant increase
in histone H3 acetylation, thus conﬁrming the efﬁcacy of
these inhibitors in suppressing deacetylase activity in a
dose-related manner (Figure 1B). PXD-101, which also sup-
presses HDAC6 (a class II HDAC), induced a signiﬁcant
increase in the acetylation of a-tubulin, similarly to the
broad spectrum HDACi, TSA,30,31 whereas MS27-275 and
API-D did not, in line with the notion that these two inhibi-
tors do not affect class II HDACs at the doses used in this
assay (Figure 1C). Blots performed at 72 h gave similar
results (data not shown).
3.1 Inhibitors of class I histone deacetylases
prevent cardiac myocyte hypertrophy in vitro
To investigate the effect on size, rat neonatal CMs were pre-
treated with HDACi for 24 h and then treated with PE, a
strong inducer of hypertrophy, for a further 48 h (Figure 2A).
Morphometric measurements indicated that treatment
with inhibitors signiﬁcantly blunted PE-induced hypertrophy
at a concentration of 1 mM for MS27-275 and PXD-101, and
0.02 mM for API-D (Figure 2B). Moreover, CMs treated with
HDACi showed morphological changes, probably due to the
fact that these HDACis prevent sarcomere re-organization
in response to hypertrophic agonists (Figure 2C).11
Expression of ANF, another parameter of CM hypertrophy,
was then assessed by qRT–PCR (Figure 2D). The amount of
ANF mRNA (messenger RNA) induced by PE treatment was
signiﬁcantly reduced by all HDACis, corroborating the data
on cell size. PE-stimulated ANF expression was signiﬁcantly
inhibited at concentrations down to 0.1 mM for MS27-275
and PXD-101, and 0.002 mM for API-D; in contrast, at
10-fold lower concentrations (0.01 and 0.0002 mM, respect-
ively for MS27-275/PXD-101 and API-D) there was little or no
effect on PE-induced ANF expression, whereas ANF
expression was very low at higher concentrations (10 and
2 mM for MS27-275/PXD-101 and API-D, respectively).
Similar results were obtained for Sk Act gene expression
(data not shown).
Time-course experiments were then performed for API-D,
the most efﬁcient drug among the three. The parameters
analysed always demonstrated the efﬁcacy of this inhibitor
in reducing PE-induced hypertrophy (see Supplementary
material online, Figure S1).
3.2 Inhibition of cardiac myocyte hypertrophy by
histone deacetylase inhibitors is not due to toxicity
HDACis can induce cell death.32 Therefore, we examined
whether HDACi administration induced cytotoxicity in CMs
by measuring LDH released by dying cells into the culture
medium. Doses of MS27-275 up to 1 mM, PXD-101 up to
0.5 mM, and API-D up to 0.02 mM did not signiﬁcantly
increase LDH release after 24 h (data not shown) or 72 h of
treatment (Figure 3A).
To evaluate potential pro-apoptotic effects of the
HDACis, we analysed genomic deoxyribonucleic acid (DNA)
degradation with a TUNEL assay (Figure 3B) and Casp3
expression with qRT–PCR (see Supplementary material
online, Figure S2). After 72 h of treatment, doses of
MS27-275 or PXD-101 up to 1 mM, and of API-D up to
0.02 mM did not increase the percentage of TUNEL-positive
CMs or the expression of Casp3 mRNA.
Thus, the HDACis did not induce toxic effects within the
range of concentrations observed to inhibit hypertrophy,
i.e.: 10.01 mM for MS27-275,  1  0.1 mM for PXD-101,
and  0.02  0.002 mM for API-D.
3.3 An apicidin derivative attenuates cardiac
hypertrophy in vivo and ameliorates cardiac
function after pressure overload
API-D is a synthetic small-molecule derivative of the natural
cyclic tetrapeptide, apicidin. We decided to use API-D to
explore the efﬁcacy in preventing cardiac hypertrophy and
heart failure induced by the TAC pressure-overload model.
Our choice for this compound was dictated by a series of
favourable properties, i.e. good pharmacokinetics in a pre-
clinical species with predicted human once-a-day oral
dosing; good tolerability and efﬁcaciousness at low doses
in pre-clinical oncology models; and no off-target activities
in counter screening (on 150 enzymes/receptors) (25 and
Phillip Jones et al., unpublished results). These properties
compare favourably with those reported for MS275, which
is not tolerated well in man and has a short T1/2,
33 and
PXD-101, a hydroxamic acid with short T1/2 and poor selec-
tivity.34 As a result of its molecular properties, API-D is
effective at a concentration lower than other compounds,
and has better pharmacokinetic properties when compared
with TSA or the other HDACis tested (25 and Phillip Jones
et al., unpublished results). In particular, the following
pharmacokinetic data were obtained for 3 mg/kg API-D
Figure 1 Dose–response relationship of the acetylation status of histone H3
and tubulin in cultured neonatal rat cardiac myocytes treated for 2 h with
each of the three histone deacetylase inhibitors used in this study. (A) Repre-
sentative western blot. (B) Densitometric analysis. Fold acetylation of histone
H3 with respect to vehicle-treated cells (mean+ SD); *P , 0.05. (C) Densito-
metric analysis. Fold acetylation of tubulin with respect to vehicle-treated
cells (mean+ SD); *P , 0.05, Statistical analysis was performed by one-way
analysis of variance with Bonferroni post hoc correction.
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in mice: AUC ¼ 5.7 mM.h; Cmax ¼ 2.6 mM; Tmax ¼ 0.42 h; T1/
2 ¼ 2.1 h. The time-course for plasma concentration
was found to be [time (h)/concentration (mM)] 0.25/2.49,
0.5/2.27, 1/1.61, 2/0.94, 4/0.35.
Thus, 9-week-old female C57BL/6 mice were injected
with API-D i.p. starting on the day after TAC, and analyses
were performed as indicated (Figure 4A). We observed sig-
niﬁcantly lower LV and heart weight to body weight (BW)
ratios in TAC-operated animals treated with API-D compared
with those that were not treated; no signiﬁcant differences
were observed within sham groups (Figure 4B and see
Supplementary material online, Tables S1 and S2), whereas
% FS (fractional shortening) did not differ between the
groups (Figure 4C). No differences were found in terms of
survival (data not shown), BW, or haematological para-
meters (see Supplementary material online, Figure S3).
Increased expression of embryonic cardiac genes (ANF,
b-MHC, and Sk Act) is a hallmark of myocardial stress
during pressure overload. To test whether in vivo API-D
treatment modiﬁes the expression of these genes, we
measured the relative abundance of these mRNAs in LV
extracts by qRT–PCR (Figure 4D). As expected, mRNA of
all three genes was signiﬁcantly higher in mice subjected
to TAC compared with sham-operated animals (P , 0.05).
In API-D-treated TAC-operated mice, the increase in b-MHC
and Sk Act was signiﬁcantly reduced. Moreover, histone H3
was more acetylated in myocardial extracts of API-D-treated
animals (Figure 4E).
We then studied the effect of API-D on myocardial func-
tional and biological parameters after 8 weeks of TAC, the
point when mice present with a decompensated form of
cardiac hypertrophy. To this end, 9-week-old female
C57BL/6 mice were injected with API-D i.p. from day 1 of
TAC, and analysed as outlined in Figure 5A. At the end
of the experiment, LV/BW ratio was found signiﬁcantly
lower in the API-D-treated TAC-operated group than in the
untreated one; no signiﬁcant differences were observed
between sham groups (Figure 5B). Other parameters of
cardiac hypertrophy, such as LV mass index, diastolic
interventricular septum thickness, and diastolic LV posterior
wall thickness were all signiﬁcantly less in the API-D-treated
TAC-operated group with respect to the untreated
counterpart (Figure 5C). LV diastolic diameter was also
signiﬁcantly less in TAC-operated mice when treated with
Figure 2 Treatment with histone deacetylase inhibitors signiﬁcantly reduces parameters of cardiac myocyte (CM) hypertrophy in vitro. (A) Schematic of treat-
ment protocol and analyses performed. (B) Representative morphometrical analysis of the cumulative frequency of CM area (given as pixels2) after treatment at
the indicated concentrations in vitro; *P ¼ 0.005 vs. phenylephrine (PE); †P ¼ 0.05 vs. PE. (C) Photomicrographs of CMs stained with phalloidin-tetramethyl rho-
damine iso-thiocyanate (actin, in red) and DAPI (nuclei, in green). (D) Dose–response relationship of atrial natriuretic factor (ANF) messenger ribonucleic acid
(mRNA) collected from CMs after treatment in vitro. Mean+ SD, normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA. *P , 0.05 vs. PE. PE, phenyl-
ephrine; PD, PD 098059. Statistical analysis was performed by one-way analysis of variance with Bonferroni post hoc correction.
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API-D. Moreover, percentage fractional shortening was sig-
niﬁcantly higher in the API-D-treated TAC-operated group
with respect to the untreated TAC-operated one (Figure 5C).
As expected, haemodynamic evaluation showed a mark-
edly depressed systolic function in untreated TAC-operated
mice. The ﬁrst derivative of LV pressure (dP/dtmax) was
found signiﬁcantly improved in the group of TAC-operated
mice treated with API-D compared with the untreated
counterpart (Table 2). Positive effects on cardiac function
were conﬁrmed also by two independent parameters of
cardiac relaxation, the minimum ﬁrst derivative of LV
pressure (dP/dtmin) and exponential t (the time constant
of LV pressure decay), suggesting a better diastolic cardiac
performance and, indirectly, reduced myocardial ﬁbrosis.
In addition, a signiﬁcantly lower Sk Act mRNA level was
measured in the LV of the API-D-treated TAC-operated
group compared with the untreated TAC-operated one
(Figure 5D); ANF and b-MHC mRNAs were slightly reduced.
To assess whether treatment with API-D decreases ﬁbrotic
reaction, hearts were processed for histology, stained with
Masson’s trichrome, and the total area affected by ﬁbrosis
(i.e. stained in blue) was measured in whole-heart sections
(Figure 6). The area of ﬁbrosis occurring with TAC (9.9 
106+ 0.8  106 mm2) was signiﬁcantly (two-way ANOVA
with Bonferroni post-test, P , 0.05) reduced by treatment
with API-D (5.5  106+ 0.5  106mm2).
No differences were found between the untreated and
API-D-treated sham-operated groups in terms of survival,
Casp3 expression (measured by qRT–PCR on RNA samples
extracted from LV tissue), and BW (see Supplementary
material online, Tables S1 and S2). Moreover, haemato-
logical parameters were within the norm for all groups
(see Supplementary material online, Figure S4).
4. Discussion
We have focused on the characterization of new HDAC
inhibitors, describing an apidicin derivative with a speciﬁc
HDAC class I inhibiting activity in particular. API-D is part
of a structurally novel family of HDAC inhibitors since it
Figure 3 Analysis of cell death. (A) Dose–response of lactate dehydrogenase
(LDH) released into the medium by cardiac myocytes (CMs) treated in vitro.
Mean+ SD. *P, 0.05 vs. phenylephrine (PE). (B) Terminal deoxynucleotidyl
transferase biotin-20-deoxyuridine 50-triphosphate nick end labelling
(TUNEL) analysis of apoptosis. Dimethyl sulphoxide (DMSO) was used as a
positive control at concentrations of 5 and 20%. *P, 0.05 vs. PE. PE,
phenylephrine; PD, PD 098059. Statistical analysis was performed by
one-way analysis of variance with Bonferroni post hoc correction.
Figure 4 In vivo administration of apicidin derivative (API-D) blunts pressure overload-induced cardiac hypertrophy. (A) Schematic of the treatment protocol
and analyses performed in the short-term in vivo study. TAC, transverse aortic constriction; Echo, echocardiography; Inv, invasive haemodynamical analysis; Grav,
gravitometrical measurements. (B) Graph of left ventricle (LV) weight to body weight (BW) ratio. Within the TAC-operated groups, the ratio increased signiﬁ-
cantly less when API-D was administered. *P , 0.001 [two-way analysis of variance (ANOVA)]. (C) Graph of fractional shortening. (D) Foetal gene messenger ribo-
nucleic acid (mRNA) expression was evaluated in LV by qRT–PCR (quantitative reverse transcription polymerase chain reaction) (mean+ SD, normalized to
glyceraldehyde-3-phosphate dehydrogenase mRNA). b-MHC, beta-myosin heavy chain; ANF, atrial natriuretic factor; Sk Act, skeletal actin; *P , 0.04; †P ¼
0.02 (two-way ANOVA). (E) Representative western blot of histone H3 acetylation status in total extracts of LV tissue obtained from TAC-operated mice with
and without API-D treatment (left). Densitometric analysis (right).
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neither contains a hydroxamic acid (as does PXD-101) nor a
benzamide moiety (as does MS27-275), but it is thought to
bind to the HDAC active site Znþ ion via a hydrated ketone
group.25 Our data demonstrate that the use of this com-
pound blunts hypertrophic cardiac growth in mice and,
thus, has positive effects on heart failure progression
without producing any obvious side effects.
Cardiac myocytes (CM) respond to stress by activating gene
expression programs. Many transcription factors have been
identiﬁed that are critical for the induction of speciﬁc
genes activated during hypertrophy.35 The post-genomic
era, however, has shown that transcription factors are not
the unique key regulators of gene expression. Epigenetic
mechanisms such as DNA methylation, post-translational
Figure 5 In vivo administration of apicidin derivative (API-D) preserves cardiac function in the long-term. (A) Schematic of treatment protocol and analyses
performed for the long-term experiments. TAC, transverse aortic constriction; Echo, echocardiography; Inv, invasive haemodynamical analysis; Grav, gravitome-
trical measurements. (B) Left ventricle (LV) weight to body weight (BW) ratio. *P , 0.001 [two-way analysis of variance (ANOVA)]. (C) Time-course of % fractional
shortening (FS), LV mass (LVM), diastolic interventricular septal thickness (IVSd), and diastolic LV posterioral wall thickness (LVPWd) for each group. *P ¼ 0.05
(two-way ANOVA). (D) Foetal gene messenger ribonucleic acid (mRNA) expression evaluated by qRT–PCR (quantitative reverse transcription polymerase chain
reaction) (mean+ SD, normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA). *P, 0.01 (two-way ANOVA).
Table 2 Haemodynamic parameters in mice after 8 weeks of treatment
Control (n ¼ 6) TAC (n ¼ 6) TAC þ API-D (n ¼ 5)
P–V loop analysis
Heart rate (bpm) 249+13 317+27a 324+28a
End-systolic volume (mL) 12.4+0.3 22.2+5.4a 15.5+4.0
End-diastolic Volume (mL) 25.8+1.9 29.2+4.2a 26.1+4.9
Elastic Elastance (Ea) (mmHg/mL) 6.7+1.2 23.3+6.2a 17.9+1.5a
Systolic function
Maximum Pressure (mmHg) 80.5+2.9 112.1+14.6a 121.7+16.2a
End-systolic Pressure (mmHg) 77.4+2.2 110.2+14.2a 115.0+17.5a
dP/dt max (mmHg/s) 4485+133 3405+501a 4776+514b
Ejection Fraction (%) 55.4+1.6 24.6+2.0a 41.6+6.0a,b
Stroke Volume (mL) 13.0+2.4 7,0+2.2a 12.1+2.5a,b
Cardiac Output (mL/min) 3.2+0.7 2.1+0.5a 3.7+0.6b
Ees 8.5+1.3 1.5+1.0
a 11.6+0.9a,b
Emax 12.5+0.6 8.1+2.3
a 15.2+0.6b
Diastolic function
End-diastolic Pressure (mmHg) 9.0+2.0 15.0+3.2a 10.0+4.0b
dP/dt min (mmHg/s) 23566+305 22989+496a 24183+550b
t_w (ms) 12.5+0.9 18.6+3.6a 13.1+1.6b
slope-EDPVR 0.5+0.3 0.8+0.2a 1.0+0.4a
aP , 0.05 vs. Control; bP , 0,05 vs. TAC. Comparisons were made using ANOVA with Neuman–Keuls correction.
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modiﬁcations of histone proteins, remodelling of nucleo-
somes, and expression of small regulatory RNAs all contribute
to regulation of gene expression and determination of cell
and tissue speciﬁcity. These mechanisms are reversible and
represent potential targets for therapeutic intervention.
The regulation of gene expression through histone acetylation
has been demonstrated to be particularly relevant and
complex for CM growth and myocardial hypertrophy.13,36,37
Class I and class II HDACs seem to have opposite effects
on hypertrophic pathways. Class II HDACs repress hypertro-
phy,9,38 whereas class I HDACs are required for some
aspects of the hypertrophic response. Inhibitors that
block the catalytic activity of both class I and class II
HDACs prevent hypertrophic responses in both isolated
myocytes and intact mice, suggesting that the predomi-
nant targets of these chemical inhibitors are class I
HDACs.11,39 Recently, it was proposed that HDAC2, among
the class I HDACs, is a major target of HDAC inhibitors
in the heart, indicating this HDAC as a target for the
treatment of cardiac hypertrophy and heart failure.14
Knockout of HDAC2 was demonstrated to increase
expression of the gene encoding inositol polyphosphate-5-
phosphatase f, resulting in constitutive activation of
glycogen synthase kinase-3beta via inactivation of Akt
and 3-phosphoinositide-dependent protein kinase-1.14 Inhi-
bition of cardiac hypertrophy in vivo by either generic or
class I-speciﬁc HDAC inhibitors was found to improve
cardiac function and blunt ﬁbrosis signiﬁcantly.12,40
Overall, our data obtained with the novel compound,
API-D, together and in agreement with the literature
suggest that the beneﬁcial effect of HDAC inhibition
includes attenuation of ﬁbrosis and reduced switching of
contractile protein isoforms.
We acknowledge the limitations of our study in that it is
relatively underpowered and that it does not compare
in vivo all the inhibitors used in the study, but the functional
improvement seen in the mice was found to be signiﬁcant
with relatively low doses of API-D. The small but signiﬁcant
blunting of hypertrophy produced with this compound may
not explain the improved heart function totally, and as yet
unknown mechanisms, apart from transcriptional-related
ones, might be involved. On this point, a very recent
report has revealed that HDACs inﬂuence cardiac function
at an extra-nuclear level:41 treatment of cardiomyocytes
with HDAC inhibitors results in an increased acetylation of
sarcomeric proteins that enhances myoﬁlament calcium
sensitivity. Muscle LIM protein—the cytosolic target of
HDAC4, a class II HDAC, and PCAF, a HAT—was found to be
central to this mechanism. Thus, protein acetylation is
another layer of regulation controlling muscle physiology
that might be targeted when using HDAC inhibitors; we do
not exclude the possibility that API-D might also affect
cardiac function through altered acetylation of sarcomeric
proteins, perhaps indirectly through an effect mediated by
class II HDACs. In fact, in that report, the class I HDAC
inhibitor, MS275, was found to have an effect that was
comparable with that of the generic HDAC inhibitors, TSA
and scriptaid.
Despite in vitro data, which clearly demonstrate reduced
expression of hypertrophy markers, data obtained in vivo
can be more difﬁcult to interpret. In fact, the expression
of ANF in vivo has been reported to be profoundly affected
in one instance,40 whereas in another report the effect of
HDAC inhibition on ANF expression was limited.12 We
observed in vivo that the ANF transcript level was increased
in API-D-treated TAC-operated mice to a similar extent as
untreated TAC-operated mice even if hypertrophy was sig-
niﬁcantly blunted in the former; on the other hand, b-MHC
and Sk Act were reduced. E. Olson’s lab reported a similar
discrepancy between in vitro and in vivo ANF levels after
the use of TSA.11,12 An enhancement of gene expression in
general is a consequence of HDAC inhibition; therefore,
generic transcriptional effects could a be reason for con-
founding mRNA expression levels in vivo.
Dissection of the mechanisms underlying HDAC inhibition
represents a continuing challenge in cardiology. In oncology,
these drugs are already under clinical trials for the treat-
ment of cancer. Because class I HDAC inhibition prevents
cardiac hypertrophy induced by pressure overload and
greatly improves heart function, HDAC inhibitory compounds
hold promise to be a new pharmacologic tool also for the
treatment of heart failure.
Supplementary material
Supplementary material is available at Cardiovascular Research
online.
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Figure 6 Apicidin derivative (API-D) reduces ﬁbrosis of hearts subjected to
transverse aortic constriction (TAC). Representative sections of whole
mouse heart subjected to TAC (left) and TAC þ API-D (right) for 4 weeks
and stained with Masson’s trichrome to evidence ﬁbrosis. Staining for ﬁbrosis
(blue) seen in the ventricle walls of TAC-only mice was reduced by the admin-
istration of API-D (2.5). Bottom, enlarged portion of heart from a TAC (left)
and TAC þ API-D (right) mouse (20).
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